Long-term data from the CheckMate 067 trial shows that about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more. The Phase III trial included 945 patients and demonstrated that combining nivolumab and ipilimumab dramatically improved outcomes for a previously fatal condition. The study found no new safety signals for the treatment and showed that survivors become increasingly likely to die of other causes as they age, signaling long-term treatment success. These findings provide hope for patients with metastatic melanoma and suggest improved care protocols based on long-term outcomes.
Source link
Long-term metastatic melanoma survival dramatically improves on immunotherapy, clinical trial finds
